Pharma
Stocks tagged with the pharma theme.
Articles in this theme
JNJ
Johnson & Johnson: a strengthening business near record highs, with almost no upside left to consensus
A 3-of-4 Financial Scorecard, 9.9% quarterly revenue growth and the best timing signals in this group (2-of-3). But the stock is just 7% below its high, valuation scores 1-of-4 sensible, and 21 analysts' $236.21 average target sits under 1% above the price, with 52% rating it only Hold. Current price: $234.20.
pharmamedtechdividend-king
PFE
Pfizer: a cheap multiple and heavy free cash flow — and the most bearish analyst coverage in this group
A 2-of-4 scorecard pairs cash-backed profits and a 19.6% free-cash-flow margin with declining revenue and earnings. The stock trades at 19x earnings, 8% below its high — but only 23% of 12 analysts rate it Buy, against 60% Hold and 17% Sell. Current price: $25.92.
pharmadividendpatent-cliff